CLINICAL_TRIALS
trial_result
· 2020-07-07
Clinical Trial Update: A Clinical Trial for Examining the Therapeutic Equivalence Between Fluticasone Propionate 100 mcg and Salmeterol 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 100/50 mcg Inhalation Powder/GSK in Patients With Asthma [Phase 3]
Summary
Phase 3 trial comparing therapeutic equivalence of Fluticasone Propionate/Salmeterol inhalation powder to Advair Diskus in asthma patients has completed.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Respirent Pharmaceuticals Co Ltd. | Conditions: Asthma | Phase 3 | Status: COMPLETED